Next, to target subtype-specific pathways, we explored the Genomics of Drug Sensitivity in Cancer (GDSC) resource for compounds directed against key DEGs in the PD1 pathway (predominant in C1) and five DEGs in the G2/M checkpoint pathway (predominant in C2) [50]. Here, PDCD1 is linked to cancer.